BGI Genomics: Controlling Shareholder Releases 7 Million Shares from Pledge and Re-Pledges 6.85 Million Shares

NightAirdropper · 2026-03-23T18:48:51+00:00

BGI Genomics announcement shows that the controlling shareholder has released 7 million pledged shares and re-pledged 6.85 million shares. Cumulative pledged shares account for 21.76% of the company's total share capital. The company's operating revenue and net profit from 2022-2024 both performed poorly, while the asset-liability ratio remained stable. Meanwhile, the company faces multiple risk warnings.

NightAirdropper

2026-03-23 18:48:51

Abstract generation in progress

BGI Genomics (300676) announced on March 20th that its controlling shareholder, Shenzhen BGI Genomics Technology Co., Ltd., has解除质押 of 7,000,000 shares pledged to Zhuhai China Resources Bank Co., Ltd. Shenzhen Branch, and has pledged an additional 6,850,000 shares to China Postal Savings Bank Co., Ltd. Shenzhen Luohu Branch and Guangdong China Resources Bank Co., Ltd. Shenzhen Branch.

As of the announcement date, BGI Holdings and its concerted parties have pledged a total of 69.47% of their holdings in the company, accounting for 21.76% of the total share capital.

According to Tianyancha, BGI Genomics was established on July 9, 2010, with a registered capital of approximately 418.317 million RMB. The legal representative is Hou Yong. The registered address is No. 8 South 1-1, Binhai Community, Meisha Street, Yantian District, Shenzhen, at BGI Time Space Center, Building B. The main business includes providing research services, precision medicine testing solutions, and health management services for research institutions, enterprises, medical institutions, and social health organizations.

Currently, the company’s chairman is Wang Jian, the secretary is Xu Qian, with 3,702 employees. The actual controller is Wang Jian.

The company has investments in 104 subsidiaries, including Innomics Inc., BGI Health Colombia S.A.S., BGI Health Uruguay S.A., BGI South Africa (Pty) Ltd., and BGI Digital Biology Technology (Shenzhen) Co., Ltd.

In terms of performance, the company’s revenue for 2022, 2023, and 2024 was approximately 7.046 billion RMB, 4.35 billion RMB, and 3.867 billion RMB, respectively, with year-over-year growth of 4.14%, -38.33%, and -11.10%. Net profit attributable to shareholders was approximately 803 million RMB, 92.9 million RMB, and a loss of 903 million RMB, with YoY changes of -45.06%, -88.43%, and -1071.68%. During the same period, the company’s asset-liability ratio was 28.88%, 26.51%, and 26.08%.

Regarding risks, Tianyancha data shows the company has 243 internal Tianyan risks, 210 surrounding risks, 36 historical risks, and 640 warning alerts.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes